London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Having 23 potential targets for TYK2 as set out in patent application surely derisks TYK2 hugely.
Having a 1 in 3 or 1 in 4 success rate against these targets surely would give us a substantial market ?
Yes, tangible news that might entice new investors. Not filing for a patent. SAR must have files for loads of patents over the years. It wouldn't make me invest. Gaining the patent probably would.
Yeah but no. We had no news on aurora for nearly 4 years. And it was bad news. At least if we get proper updates we can make our own investment decisions. Rather than being kept in the dark. It's a public company not a private one. And all investors are entitled to the same information.
I agree Stoney but I think we've got the point where we want news, any news. There was an interview with Tim a few years ago where he untered mmortal words "no news is good news'. These are wise words when investing in bio. Statistically speaking there is more chance that SRA737 will fail than get approved just as there isn't much chance TYK2 will get past P2. That not me giving a opinion that's bio on general. Not many drugs make it to market. It would probably be unheard of for a company to develop 2 or 3 that make it to market. Food for thought.
Wow...that does not sound very good...substitute payments for patents and you might get my drift:)
Do we think the will have filed additional european and asian payment for the additional...must have.
I know we already have tyk2 patents for europe but i would have thought sar would have done the same.
The US patents would be the icing on the cake though.
Hi Potnak - as mentioned in the filing this application is based on the already patented compounds by SAR disclosed in WO2008/139161 and WO2010/055304. Further as described in the new filing these are subgroups of original compounds which IMHO was worthy of specific coverage in the June 2019 Portfolio Update.
More speculation is - why have SAR chosen not to state the new filing. Especially when we already knew of the appeal that was going through. The new filing is based on the very data that SAR still hasn’t formally released and which TM refers to as compelling and significant - why have they not released this data that was used to select these ‘subgroups’ that are being cited in the filing as able to treat 23 conditions and diseases??
I've said before. I don't like sticking up for the company because I do think comms are poor. In this case, how many companies publish when they have applied for a patent? They only publish when they get the patent. If the patent isn't granted the SP will crash, not because it is bad news but because this is AIM and fear\greed drive the market. It's likely the patent won't be granted on the first attempt so why disrupt the market until it is?
However, they could have said TYK2 is showing promising indications in 23 diseases and Sareum will be pursuing this promisuing data.
Hi Ahfam - any opinion on why this new patent filing had not been announced by SAR? It is clearly news that would be of interest to shareholders
lumphammer, I am sure it wouldn't be the first time someone else was privy to info. we are not. I would like to know what Searl's friend was informed which motivated him to partake in the previous fundraising.
Morning Fadec, great find and thank you!
The asthma link is what interested me with the preliminary info shared earlier this week on possible inhaled forms of Tyk2 inhibition. TYK2 really is the elephant in the room, CHK1 is out there (hopefully) doings its thing, but Sareum monetising the ULTRA hot asset they have in TYK2 is the game changer for me.
If the institution that bought on thé last raise was told about the content of the patent application then that would have been preferential information denied to us
so we have a *subgroup of compounds* that can be used effectively for treatment of 23 diseases or conditions.
Bring it on.
They could have also mentioned it in the RNS dated 13 June 2019 - Portfolio Update.
Hi All - Fadec great find.......
Based on the date of the patent filing (13 March 2019) I'm a bit confused as to why this critical filing of a new patent was not covered in the RNS dated 04 March 2019 issuing the HALF-YEARLY RESULTS ENDED 31 DECEMBER 2018. This is the RNS that cited the deal comparisons and valuations. Surely they knew this was about to be filed and furthermore, this was news that was relevant and demonstrating good progress being made by SAR?????
Based on the announcement of SDC-1801 and SDC-1802 in late 2018 and the following extract from the new patent submission it would appear this patent application is for the specific new compounds;
SUMMARY OF THE INVENTION
 It has now been found that a subgroup of compounds of the type disclosed in WO2008/139161 and WO2010/055304 are particularly effective inhibitors of TYK2 kinase and, furthermore, demonstrate selectivity against TYK2 compared to the other three JAK kinases JAK1, JAK2 and JAK3. Such compounds therefore provide a means of treating inflammatory conditions and diseases whilst exhibiting reduced or substantially no side effects associated with JAK1, JAK2 or JAK3 inhibition.
Further on in the patent application it mentions the diseases and treatments (RA, IBD, MS, asthma, allergic inflammation and transplant rejection) discussed in earlier posts plus our elusive LUPUS.
Use in Treating Diseases and Conditions Other Than Multiple Sclerosis
 Whilst the TYK2 inhibitory activity of the compounds of formula (1) can be made use of in the treatment of autoimmune diseases, it can also be put to good use in the treatment of a range of other inflammatory diseases, as well as immunological and allergic diseases. Accordingly, the invention also provides a method of treating a disease or condition in a subject wherein the disease is any one or more diseases or conditions selected from:
(a) skin inflammation due to radiation exposure; (b) asthma; (c) allergic inflammation; (d) chronic inflammation; (e) an inflammatory ophthalmic disease; (f) dry eye syndrome (DES, also known as keratoconjunctivitis sicca or dysfunctional tear syndrome); (g) uveitis (e.g. chronic progressive or relapsing forms of non-infectious uveitis); (h) insulin- dependent diabetes (Type I); (i) Hashimoto's thyroiditis; (j) Graves' disease; (k) Cushing's disease; (l) Addison's disease (which affect the adrenal glands) (m) chronic active hepatitis (which affects the liver); (n) polycystic ovary syndrome (PCOS); (o) coeliac disease; (p) psoriasis; (q) inflammatory bowel disease (IBD); (r) ankylosing spondylitis; (s) rheumatoid arthritis; (t) systemic lupus erythematosus; (u) myasthenia gravis; (v) transplant rejection (allograft transplant rejection); and (w) graft-versus-host disease (GVDH);
Yes followed many US patents, it’s a new Patent!
My bad...should have read properly, it is appeal.
You would think that with the original application being 2013 and the appeal hearing done it would get some sort of priority status.
Well done that man....i dont care if it goes up 10% or 300%, if we secure that patent the mm's wont see a single share from me.
Fadec, have you seen appealed patents before...have you any guesses at a possible timeline?
Was the appeal hearing march 7 then...is this a completly new submission?
Any views welcome...
The US patent for the TYK2 is in process on USPTO under Reader-John!
And not in just for what we know ie RA, IBD, MS etc, but also asthma, allergic inflammation and transplant rejection among others, always wondered about allergic reactions and asthma as is own body’s overreaction is the problem, imagine that the next in front line treatment for them will be lucrative!
Appl. No.: 16/351620
‘IMO, It isn't an issue if we licence it out but for takeovers. It would make it very messy.’
I suppose that shows how we all look at things differently? My view is the exact opposite; the US patent not being granted (yet?) for tyk2 is more of an issue for licensing the individual compound but not an issue in the event of a full takeover as they effectively have the master-patent in the latter situation.
IMO, It isn't an issue if we licence it out but for takeovers. It would make it very messy. The company taking over would probably have to buy SKIL too and maybe both versions of TYK2 and if they are going to do that then why not take the whole company? it's a bit much if you only want TYK2 autoimmune. The lack of a worldwide patent might be the reason we haven't got a deal yet.
Hi stoney, everything you say there is correct except that the appeal was in early april or may i think so i was hoping that around now we would have heard that it had been granted.
I get the point that thoth made re skill but i think we would all rather that this patent was awarded directly......about 2 or 3 years ago thoth uncovered the original submission doc that reader put forward clearly in Sareums view why both were distinct and seperate from each other and it was a great read.
Im hoping we can get this over the line...the just might be the catalyst that our bod are waiting for!
Hi All - I may be wrong here (and I still believe we are due an update on this) but I was of the understanding that our patent application was rejected as it was too similar to a previous application we were successful with. SAR appealed this decision and this was heard in the US Patents Office and SAR were represented by a Patent Lawyer (can't recall who) last year. I certainly recall a flurry of debate on the BB regarding this.
I think the US Patent Office had decided the TYK2 application was too similar to our Oxazole Tyrosine Kinase Inhibitors (FLT3, FLT4 and Aurora kinases) granted under US 20140275041 A1 (Jan 2014)
I also recall Thoth claiming it was not really an issue as we had patents on the SKIL platform that created the compounds therefore protected????
Agree it would be good to have an update on this and better still a specific TYK2 patent.